Corbus Pharmaceuticals Holdings, Inc. (CRBP)

CRBP Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	0.88	3.94
Revenue Growth (YoY)	-	-	-	-77.61%	-89.11%
Cost of Revenue	32.22	31.17	16.14	36.45	98.27
Gross Profit	-32.22	-31.17	-16.14	-35.56	-94.33
Selling, General & Admin	16.5	13.91	18.7	20.43	28.48
Operating Expenses	16.5	13.91	18.7	20.43	28.48
Operating Income	-48.72	-45.08	-34.84	-55.99	-122.81
Interest Expense	-1.87	-3.86	-3.1	-2.71	-1.13
Interest & Investment Income	6.31	1.64	0.96	0.88	0.1
Currency Exchange Gain (Loss)	-	-	-0.43	-0.38	-0.45
Other Non Operating Income (Expenses)	4.07	2.7	0.05	12.56	13.02
EBT Excluding Unusual Items	-40.21	-44.6	-37.35	-45.64	-111.27
Legal Settlements	-	-	-5	-	-
Pretax Income	-40.21	-44.6	-42.35	-45.64	-111.27
Net Income	-40.21	-44.6	-42.35	-45.64	-111.27
Net Income to Common	-40.21	-44.6	-42.35	-45.64	-111.27
Shares Outstanding (Basic)	11	4	4	4	3
Shares Outstanding (Diluted)	11	4	4	4	3
Shares Change (YoY)	152.23%	3.76%	1.85%	57.23%	22.28%
EPS (Basic)	-3.68	-10.31	-10.15	-11.15	-42.72
EPS (Diluted)	-3.68	-10.31	-10.15	-11.15	-42.72
Free Cash Flow	-41.79	-36.1	-37.56	-48.24	-100.17
Free Cash Flow Per Share	-3.83	-8.34	-9.01	-11.78	-38.46
Operating Margin	-	-	-	-6350.09%	-3119.20%
Profit Margin	-	-	-	-5176.38%	-2826.08%
Free Cash Flow Margin	-	-	-	-5470.98%	-2544.18%
EBITDA	-48.13	-44.44	-34.07	-54.99	-121.69
D&A For EBITDA	0.59	0.64	0.76	1	1.12
EBIT	-48.72	-45.08	-34.84	-55.99	-122.81

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q